NCT07495033尚未招募3 期
Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 260
- 试验地点
- 1
- 主要终点
- Change from Baseline in FVC(mL) at Week 52
研究概览
简要总结
Interstitial lung disease (ILD) is a common pulmonary manifestation in chronic tissue diseases (CTD), significantly affecting patient's prognosis.
The main purpose of this study is to evaluate the efficacy of telitacicept compared with placebo in slowing down the decline in lung volume in patients with interstitial lung disease associated with connective tissue disease (CTD-ILD) on the basis of standard treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary informed consent provided;
- •Male or female aged ≥ 18 years old;
- •Documented diagnosis of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), Sjogren's syndrome (SjD) , Systemic sclerosis（SSc）,or mixed connective tissue disease (MCTD) in accordance with internationally recognized classification criteria;
- •Diagnosis of ILD on High Resolution Computed Tomography (HRCT) with disease extent of greater than or equal to (≥) 10% of the whole lung (WL-ILD);
- •During screening, FVC%Pred ≥ 45%;
- •During screening, DLCO%Pred(corrected for hemoglobin) ≥ 30%;
- •Stable standard treatment was received before randomization to control ILD and/or connective tissue disease;
排除标准
- •Diagnosis of Interstitial lung disease other than CTD-ILD;
- •ILD progresses rapidly within 12 weeks before screening or during screening;
- •During screening, HRCT showed severe emphysema (the degree of emphysema exceeded that of ILD);
- •Obstructive pulmonary disease (pre-bronchodilator Forced Expiratory Volume (FEV1) /FVC <0.7);
- •Pulmonary arterial hypertension requiring therapy, as determined by the investigator;
- •Having diffuse alveolar hemorrhage (DAH) or other pulmonary conditions that may have confounding effects, as well as related signs or symptoms;
- •Unable to complete the pulmonary function test, or requiring supplementary oxygen supply;
- •Clinically significant laboratory abnormalities;
- •QTc interval prolongation on ECG;
- •Allergy to human or mouse-derived biological products, or history of other drug allergies, and the investigator deems that the patient is not eligible to participate.
- •Previous treatments received:
- •Previous or planned organ transplantation or bone marrow transplantation;
- •Plasma exchange or extracorporeal light separation exchange was performed within 6 months before randomization, or a plasma filtration device was used;
- •Any targeted BLyS or APRIL drug treatment was received within 12 weeks before randomization;
- •Biologic therapy was received within 12 weeks or within 5 half-lives of the corresponding drug (whichever is longer) before randomization;
- •B-cell depletion drugs were used within 6 months before randomization;
- •Non-biological systemic immunosuppressive drugs other than standard treatment were used within 4 weeks before randomization;
- •Anti-fibrotic drugs were used within 4 weeks before randomization;
- •Cyclophosphamide treatment was received within 6 months before randomization;
- •Cytotoxic drugs were used within 6 months before randomization;
- •Intravenous or intramuscular glucocorticoids were used within 4 weeks before randomization;
- •Major surgery within 12 weeks prior to screening or planned during the duration of the study；
- •Received or plan to receive any live vaccine within 28 days prior to randomization;
- •Participation in any clinical trial 28 days prior to randomization or within 5 times the half-life of an investigational drug (whichever is longer);
- •has active hepatitis or a history of severe liver disease；
- •Acute or chronic infection requiring treatment;
- •suffered from symptomatic herpes zoster within 12 weeks prior to screening;
- •Active tuberculosis；
- •HIV infection;
- •History of malignant tumors；
- •Significant cardiovascular disease, liver, kidney, respiratory, endocrine or hematologic disease, or other medical conditions that, in the opinion of the investigator, would preclude the subject's participation in the study or require hospitalization during the trial;
- •History of drug or alcohol abuse or dependence；
- •Pregnant or lactating women, and those intending to become pregnant during the trial;
- •Patients considered unsuitable by the investigator to participate in the trial ;
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive placebo in addition to standard therapy.
干预措施: Placebo (Drug)
Telitacicept
Experimental
Participants will receive elitacicept in addition to standard therapy.
干预措施: Telitacicept (Drug)
结局指标
主要结局
Change from Baseline in FVC(mL) at Week 52
时间窗: Baseline and Week 52
次要结局
- Change from Baseline in FVC%Pred at Week 52(Baseline and Week 52)
- Change from Baseline in DLCO%Pred at Week 52(Baseline and Week 52)
- Time to ILD Progression or Death(The time from Baseline to Week 52)
- Change from Baseline in Quantitative Interstitial Lung Disease in the Whole Lung (QILD-WL) At Week 52(Baseline and Week 52)
- Change from Baseline in Quantitative Measures of Lung Fibrosis (QLF) in the Whole Lung At Week 52(Baseline and Week 52)
- the proportion of subjects with a QILD-WL score reduction ≥2% at week 52(Baseline and Week 52)
- The proportion of subjects who showed a ≥5% decrease in FVC (mL) from baseline at week 52;(Baseline and Week 52)
- The proportion of subjects who showed a ≥10% decrease in FVC (mL) from baseline at week 52;(Baseline and Week 52)
- Change from Baseline in the short form health survey（SF-36） at Week 52(Baseline and Week 52)
- Change from Baseline in Patient global impression of severity（PGI-S） at Week 52(Baseline and Week 52)
- Changes from baseline in immunological markers（IgG、IgA、IgM、CD19+ B）at Week 52(Baseline and Week 52)
- Incidence and severity of adverse events(From signing of informed consent until 4 weeks after the last dose.)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung DiseaseNCT07420439Intergroupe Francophone de Cancerologie Thoracique108
进行中（未招募）
3 期
泰它西普注射液治疗结缔组织病相关间质性肺疾病患者的 III 期临床试验结缔组织病相关间质性肺疾病CTR20260545荣昌生物制药（烟台）股份有限公司
招募中
2/3 期
Smaller vs. Larger Probes for Lung Biopsies in Interstitial Lung Disease: A Study on the Safety and Effectiveness comparison between the two intervention modalities.CTRI/2025/08/092221National Institute of TB and Respiratory Diseases60
尚未招募
1 期
CAR-DC for End-Stage IPFNCT07329959Second Affiliated Hospital, School of Medicine, Zhejiang University8
尚未招募
不适用
Development of a tool to identify patients with interstitial lung diseases and without interstitial lung diseasesCTRI/2024/03/064176Cipla Ltd300